Fannin Partners is an early-stage life sciences product development group that advances therapeutic and platform programs across ophthalmology, oncology, immunology, fibrosis, and reproductive health.
The company develops Raptamer therapeutics using an in-house discovery platform to generate high-affinity peptidomimetic DNA oligomers and partners with academic and industry collaborators to translate scientific breakthroughs into clinical development.
Leadership & Board
Current Number of Employees34
Current LinkedIn Followers4,614
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$300K
Total Amount Raised$300K
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$300K
Latest Funding Amount$300K
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Fannin Partners had 34 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
34Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Fannin Partners had 4,614 followers as of October 5, 2026. The number of followers increased by 8 (0.17%) week-over-week.
4,614Latest Followers Count
8(0.17%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.